MarketScreener

Veracyte, Inc. Reports NRG/RTOG 0815 Analysis Shows Decipher Prostate Genomic Classifier Predicts Benefit From Adding Short-Term Androgen Deprivation Therapy To Dose-Escalated ...

Veracyte, Inc. announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology ...
MarketScreener

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026. SOU ...